Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2020.2800
Abstract: Importance Despite several recent reports on the elevated risk of bullous pemphigoid in patients with type 2 diabetes treated with dipeptidyl peptidase–4 (DPP-4) inhibitors, evidence on the absolute risk and comparative safety against other antidiabetics… read more here.
Keywords: dpp inhibitor; dpp inhibitors; bullous pemphigoid;
The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice
Sign Up to like & getrecommendations! Published in 2018 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.12498
Abstract: To clarify the effects of a dipeptidyl peptidase‐4 (DPP‐4) inhibitor on whole‐body energy metabolism, we treated mice fed a high‐fat diet (HFD) with teneligliptin, a clinically available DPP‐4 inhibitor. Teneligliptin significantly prevented HFD‐induced obesity and… read more here.
Keywords: inhibitor; teneligliptin; obesity; dpp ... See more keywords
DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.21966
Abstract: Studies have shown that the DPP‐4 inhibitor was effective in improving skin damage in patients with psoriasis, but the exact mechanism was not known. To investigate the therapeutic effects of linagliptin in mice with type… read more here.
Keywords: mapk inflammatory; dpp inhibitor; group; psoriasis ... See more keywords
Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07067-w
Abstract: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are antidiabetic drugs that improve cardiovascular outcomes. Hemoglobin and hematocrit values increase after SGLT-2 inhibitor administration. Although these factors increase blood viscosity and the risk of cardiovascular disease, SGLT-2 inhibitors… read more here.
Keywords: sglt inhibitor; inhibitor; erythrocyte deformability; deformability ... See more keywords
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology International"
DOI: 10.1007/s12072-020-10122-1
Abstract: Management of type 2 diabetes mellitus (T2DM) in patients with liver cirrhosis is complex and suboptimal, but no clinical trial has adequately investigated antidiabetic drug use for such patients. We evaluate the risk of mortality,… read more here.
Keywords: users nonusers; cirrhosis; liver cirrhosis; inhibitor users ... See more keywords
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Diabetes and Metabolic Disorders"
DOI: 10.1007/s40200-021-00833-z
Abstract: Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. We studied in… read more here.
Keywords: clinical outcomes; dpp; cohort; covid ... See more keywords
The DPP‐4 inhibitor saxagliptin ameliorates ox‐LDL‐induced endothelial dysfunction by regulating AP‐1 and NF‐&kgr;B
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2019.01.008
Abstract: Abstract Diabetes‐associated cardiovascular complications are the leading cause of death for diabetic patients. Dipeptidyl peptidase 4 (DPP‐4) inhibitor agents, known as gliptins, are a class of potent anti‐glycemic agents developed to treat diabetes. Recently, gliptins… read more here.
Keywords: dpp inhibitor; adhesion; ldl induced; saxagliptin ... See more keywords
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Sign Up to like & getrecommendations! Published in 2019 at "Mayo Clinic proceedings"
DOI: 10.1016/j.mayocp.2019.06.010
Abstract: OBJECTIVES To estimate inappropriate dosing of dipeptidyl peptidase-4 (DPP-4) inhibitors and to assess the risk of emergency department visits, hypoglycemia, and mortality in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)… read more here.
Keywords: dipeptidyl peptidase; adjustment; dpp inhibitor; dose adjustment ... See more keywords
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Primary Care Diabetes"
DOI: 10.1016/j.pcd.2021.12.008
Abstract: Introduction This systematic review and meta-analysis aimed to synthesize the latest evidence on the effect of dipeptidyl peptidase-4 (DPP-IV) inhibitor in patients with COVID-19. Methods We performed a systematic literature search from the PubMed, Scopus,… read more here.
Keywords: meta analysis; inhibitor; mortality; dpp inhibitor ... See more keywords
Once-weekly oral antidiabetic agent and treatment satisfaction
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1359519
Abstract: We read with great interest the article by Handelsman and colleagues, reporting that a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin was non-inferior to a once-daily sulfonylurea glimepiride as add-on therapy to metformin in type 2… read more here.
Keywords: satisfaction; agent; dpp inhibitor; treatment satisfaction ... See more keywords
Formulation and optimization for DPP-4 inhibitor nanomicelles using response surface methodology
Sign Up to like & getrecommendations! Published in 2019 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2019.1701003
Abstract: Abstract Objective: Dipeptidyl peptidase-4 (DPP-4) inhibitors are the oral antidiabetics that inhibits the enzyme DPP-4. The main aim of study was to formulate, statistically optimize and characterize the polymeric nanomicellar (PNM) formulation of DPP-4 inhibitor… read more here.
Keywords: methodology; surface; formulation; drug ... See more keywords